Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide ... - Nature

An open-label, non-randomized phase II clinical trial at Shanghai Public Health Clinical Center enrolled adult PLWH on ART with suppressed HIV viral load. Participants received ASC22 (1 mg/kg) and chidamide for 12 weeks, with 11 visits over 24 weeks. Primary outcomes measured changes in HIV DNA, secondary endpoints included CA HIV RNA and plasma HIV viral loads, and CD4/CD8 ratios. Adverse events were monitored, and statistical analysis used repeated measures ANOVA, paired t-tests, and correlation analyses.